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动药非诺贝特可明显减少小鼠大脑中动脉阻塞(middle cerebral artery occlusion，
MCAO)后脑梗死体积，并且这种保护作用不依赖于其外周降脂效应，而与其直
接激动 PPARα受体，减轻脑缺血后的氧化应激反应，抑制 VCAM 和 ICAM 的








及 PPARα的新型高效激动剂 OEA 在脑缺血损伤中作用及特点。本论文主要采用
整体动物脑缺血模型，通过对神经功能缺失评分、脑梗死体积、脑水肿程度等指
标，阐明 OEA 对小鼠 局灶性脑缺血保护作用的剂量依赖性时间依赖性；采用荧
光定量 PCR 及 Westernblot 分别检测脑缺血后脑组织 PPARα 变化特点及 PPARα
激动剂 OEA 对脑缺血损伤后 PPARα 表达的影响。实验结果表明，OEA 剂量及
时间依赖性的保护小鼠局灶性脑缺血急性损伤，有效剂量为 20 mg•kg-1 和 40 















在脑缺血损伤后显著下降，而且在再灌后 6 h 和再灌后 24 h 存在两个表达峰值；
给予 OEA 后 PPARα mRNA 表达量显著提高，仍然存在两个表达峰值，即再灌


































Peroxisome proliferator-activated receptors (PPARs) are a group from the 
ligand-activated nuclear transcription factor and a member of the nuclear receptor 
superfamily. Peroxisome proliferator-activated receptor α (PPARα) is a subtype of 
PPARs, it is the lipids, fatty acids, and lipoprotein metabolism regulator. PPARα 
ligands can be divided into natural ligands and synthetic ligands. Natural ligand are 
mainly from the diet and body metabolites, such as long-chain polyunsaturated, 
including oleic acid, linoleic acid, arachidonic acid and so on. Synthetic ligands are 
mainly fibrates, such as WY14643, fenofibrate, etc.Cerebral ischemia is one of high 
incidence in China. Cerebral ischemic injury was mainly caused by transient or 
persistent ischemia. PPARα agonist fenofibrate can be significantly reduced cerebral 
infarct volume after middle cerebral artery occlusion (middle cerebral artery occlusion, 
MCAO) in mice. And this protective effect does not depend on its lipid-lowering of 
peripheral, Instead PPARα receptor was directly excited and reduced post-ischemic 
oxidative stress and inhibited the expression of VCAM and ICAM and reduced 
inflammation. Recently, studies have reported that the infarct volume after cerebral 
ischemia expanded in PPARα knockout mice than wild-type mice,it further suggests 
that PPARα may be directly involved in neural protection after cerebral ischemia 
Therefore, PPARα is is one of the hot spots in cerebral ischemia.  
    Oleyletheanolamide (OEA) is a naturally occuring lipid that binds with high 
affinity to the PPARα, severs as an endogenous agnoist of PPARα. In the excited brain 
damage such as brain trauma, neurons release of OEA that play a significant 
neuroprotective effect. This paper discusses whether PPARα could be used as a 
treatment for ischemic brain injury and what is the role of PPARα agonist OEA in 
cerebral ischemic injury. In this paper，using animal model of cerebral ischemia, 
neurological deficit scores,the infarct size, brain edema and other indicators being 















effect on in focal cerebral ischemia in mice. Fluorescent quantitative PCR and 
Westernblot were been used to detect the changes of PPARα and the effect of OEA on 
PPARα in cerebral ischemic injury. The results show that effective dose of OEA is 20 
mg•kg-1 and 40 mg•kg-1 and the optimal therapeutic time point of the same time of 
reperfusion. Compared with the normal group, PPARαmRNA expression significantly 
decreased after cerebral ischemia, and there are two expression peaks in 6h after 
reperfusion and 24 h after reperfusion. OEA significantly increased the expression 
PPARα mRNA, and there are still two expression peaks in 3 h after reperfusion and 
24 h after reperfusion. OEA can significantly enhance the expression of PPARα 
protein, and there is an expression of the peak at 24 h after reperfusion. 
key words: Oleoyl ethanolamine; middle cerebral artery occlusion; cerebral ischemia; 
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护 作 用 主 要 是 通 过 激 动 过 氧 化 物 酶 增 殖 物 激 活 受 体 α (peroxisome 
proliferator-activated receptor α, PPARα)产生[6]。PPARα可望成为治疗脑缺血的新
靶点。 
1.1 过氧化物酶体增殖物激活受体-α 
1.1.1 PPAR 的发现及分类 
PPAR 是过氧化物酶体激活受体的简称，在此之前人们一直以为 PPAR 是一























PPAR 三种亚型均由不同的基因编码，其中 PPARα是由 468 个氨基酸残基
组成，位于鼠 15 号染色体，人 22 号染色体。和其他核受体类似[12]，PPAR 是由
六个结构域组成的（A-F）（图 1.1）。其中 N 端的 A/B 结构域具有非配体依赖的
反式激活功能（AF-1）,该结构域在三种亚型中的保守性比较低，A/B 结构域上
还具有蛋白磷酸化位点，中间的 C 结构域是 DNA 结合域（DNA binging domain），
又称 DBD,它含有两个锌指结构，这样能使受体特异性地结合到靶标 DNA 上，
同时该区域还具有弱的二聚化，该区域的保守型很高。D 结构域为铰链区，它连




所必需的。该区域具有较高的序列保守性，C 端 F 域的功能还不是非常清楚[13-15]。 
 
 
图 1.1 PPAR 结构域组成 
PPAR 通过与其靶基因如酰基辅酶 A 氧化酶（AOX）和脂肪酸结合蛋白的启
动子中的过氧化物酶体增殖剂反应元件（Peroxisome proliferator response 
element，PPRE）结合而发挥转录调控功能。PPRE 是由两个半位组成的，它们
















个核苷酸。PPAR 通过与视黄醛 X 受体（Retinoid X Receptor，RXR）形成异源
二聚体后结合到 PPRE 上，其中的 PPAR 结合在 PPRE 的 5’半位上，RXR 结合在












的亲和力 高，花生四烯酸通过脂氧合酶途径合成的衍生物 8-s 羟基二十碳四烯
酸（8s-HETE）和白三烯 B4(LTB4)与 PPARα 的亲和力比脂肪酸本身还高[21]。而
前列环素是 PPARβ 的内源性配体，二十碳五烯酸、花生四烯酸以及一些二十烷
酸类衍生物可能是 PPARβ 的天然配体。PPARγ 的天然配体主要以多不饱和脂肪
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